NCT04158245 - 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

April 3, 2023

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

18F-fluciclovine PET Scan

The use of 18F-fluciclovine PET scanning will allow a more sensitive assessment of mCRPC patients at the initiation of systemic therapy and changes observed in 18F-fluciclovine PET will correlate better with the serologic changes in PSA, allowing superior disease monitoring, as compared to conventional imaging modalities. In addition, 18F-fluciclovine PET will detect heterogeneity in disease response and thus identify potential lesions amenable to targeted therapy.

Trial Locations (1)

70112

Tulane Cancer Center Clinic, New Orleans